Acorda Therapeutics Launches ZANAFLEX CAPSULES for the Management of Spasticity in People with MS and Spinal Cord Injury

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Apr 4, 2005 - Acorda Therapeutics(R) announced today that it has launched ZANAFLEX(R) CAPSULES (tizanidine hydrochloride), a new, capsule formulation of tizanidine, a leading treatment for spasticity in the United States. Acorda acquired ZANAFLEX(R) CAPSULES and ZANAFLEX(R) (tizanidine hydrochloride) tablets from Elan Corporation, plc (NYSE: ELN) in July 2004. Elan will manufacture ZANAFLEX(R) CAPSULES for Acorda at its Athlone, Ireland facility.

ZANAFLEX(R) CAPSULES are a short-acting drug for the management of spasticity. Spasticity refers to the often painful involuntary tension, stiffening or contractions of muscles that results from neurological conditions such as spinal cord injury (SCI) and multiple sclerosis (MS). More than 500,000 people in the United States suffer from spasticity.